Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 7/20 | 0.41 |
| ▸ | EIF4E | P06730 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | TRPC3 | Q13507 | 1/20 | 0.34 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.34 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.34 |
| ▸ | PIM1 | P11309 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3540062 | 0.90 | PIM1 (0.40) | PIM1 | |
| SCHEMBL3538082 | 0.86 | SHMT2 (0.43) | HTR2CPOLBTRPC3TRPC6PROKR1 | |
| SCHEMBL3540873 | 0.86 | ALDH1A1 (0.47) | HTR2CSCN9AKCNH2 | |
| SCHEMBL3542155 | 0.85 | PIM1 (0.42) | HTR2CPROKR1PIM1 | |
| SCHEMBL3542242 | 0.84 | HTR2C (0.48) | HTR2CTRPC3TRPC6 | |
| SCHEMBL3536849 | 0.83 | HTR2C (0.60) | HTR2CTRPC3TRPC6 | |
| SCHEMBL3541782 | 0.83 | HTR2C (0.53) | HTR2CTRPC3TRPC6 | |
| SCHEMBL3538068 | 0.83 | CPT1A (0.41) | HTR2CTRPC3TRPC6 | |
| SCHEMBL3541503 | 0.83 | RAB9A (0.38) | HTR2CTRPC3TRPC6PROKR1 | |
| SCHEMBL3544618 | 0.81 | CCNT1 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645773-B2 | Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase | HOFFMANN-LA ROCHE INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20070167622-A1 | [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome | GILLESPIE PAUL | 2007-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167622-A1 | [2-(3-chloro-phenyl)-thiazol-4-yl]-(octahydro-quinolin-1-yl)-methanone; azocan-1-yl-[2-(2,3-dichloro-phenyl)-thiazol-4-yl]-methanone; type II diabetes mellitus and metabolic syndrome | GOT2, PC, CYP11B2 | HTR2C 422/4885EIF4E 3300/4885POLB 2546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.